Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance... see more

TSXV:XRTX - Post Discussion

XORTX Therapeutics Inc > Strong BUY initiated, now 1.80 target $17.50
View:
Post by moneywinner1 on Jun 06, 2022 12:29pm

Strong BUY initiated, now 1.80 target $17.50

XRTX Analyst Research

XRTX Analyst Ratings

CONSENSUSStrong Buy
target price $17.50 USD 
Comment by moneywinner1 on Jun 06, 2022 3:17pm
Opositive news and this one is going to go Targent at Nasdaq $17.50 USA 
Comment by aussyspitz on Jun 06, 2022 7:02pm
Do you have a link to the actual analyst rating?
Comment by vitalina2233 on Jun 06, 2022 8:47pm
can you please provide the link  Papi
Comment by moneywinner1 on Jun 06, 2022 11:37pm
Strong BUY initiated, now 1.80 target $17.50 XRTX Analyst Research XRTX Analyst Ratings CONSENSUSStrong Buy target price $17.50 USD 
Comment by lscfa on Jun 07, 2022 9:27am
It's a BS lie without a link. Alliance has a $11 cdn tp. https://europac.bluematrix.com/sellside/EmailDocViewer?encrypt=3d118b2d-89c3-40dc-b38e-8ba0270761f3&mime=pdf&co=Europac&id=nick@alpineequityadv.com&source=mail
XORTX Therapeutics Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities